Callan JMB Signs Manufacturing Oversight, Federal Deployment, and Commercialization Agreement of Multi-Asset Therapeutic Pipeline with Attune for Approximately $50 to $75 Million in Total Revenue

Core Insights - Callan JMB Inc. has entered a strategic teaming agreement with Attune Biotech to enhance federal contract capabilities and expedite the deployment of Attune's therapeutic pipeline [1][2][6] Group 1: Agreement Details - Callan JMB will provide federal oversight services, including quality assurance, compliance with BARDA contracts, FDA audit readiness, and supply chain governance [2][5] - The partnership aims to generate approximately $50 to $75 million in combined revenue over the next five years, with Callan JMB's share estimated at $25 million to $45 million [5] Group 2: Operational Capabilities - Callan JMB has experience managing national stockpile assets for various federal agencies, allowing for immediate deployment capabilities that typically take years to establish [3][6] - A surge-readiness simulation was successfully completed, validating the platform for 24-hour emergency deployment and regional distribution within 48 hours [4] Group 3: Attune's Therapeutic Pipeline - Attune's pipeline includes Lodonal, a TLR4 antagonist for immune restoration, MENK-201, a peptide therapeutic for HIV and pancreatic cancer, and Cytocide-100, an antimicrobial platform [7][8][9] - Lodonal is currently in development across five clinical programs and has transitioned to fully U.S.-based cGMP production with a validated surge capacity of over 500,000 units [7]